The Longevity Fund

The Longevity Fund is a venture capital investment firm established in 2011 and located in San Francisco, California. The firm focuses on investing in early-stage companies, specifically in the seed and series A phases, that operate within the life sciences, digital health, oncology, and impact investing sectors. With a commitment to advancing human longevity, The Longevity Fund aims to support innovative solutions that enhance health and extend life.

Laura Deming

General Partner

22 past transactions

Loyal

Series A in 2021
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.

Edocate

Seed Round in 2021
Edocate operates a medical simulation platform focused on chronic disease management and medical education. The platform allows users to create unique virtual patient cases across various therapeutic areas, facilitating engagement with healthcare professionals. It offers self-based learning tools for continuous training and assessment, enabling medical education providers to develop and disseminate their own educational content efficiently. Additionally, Edocate's platform provides insights into healthcare professional decision-making, clinical gaps, variability in care, prescription patterns, guideline compliance, and patient outcomes, contributing to improved healthcare delivery.

Circumvent

Seed Round in 2020
Circumvent Pharmaceuticals is seeking to address the significant unmet need of neurodegenerative disease patients. Circumvent is targeting heritable forms of neurodegeneration to enable drug discovery and development in both rare and common forms of neurodegenerative disease. Circumvent is funded by NIH/NINDS, YC Bio, Heritage Provider Network, the Longevity Fund, and additional investors.

Rubedo Life Sciences

Seed Round in 2020
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Elevian

Venture Round in 2020
Elevian, Inc. is a biotechnology company based in Menlo Park, California, founded in 2017. The company focuses on developing medicines that aim to restore regenerative capacity and address age-related diseases. Elevian's research centers on the Growth Differentiation Factor 11 (GDF11) protein and other circulating blood factors that stimulate regeneration in various tissues, including the brain, heart, pancreas, and muscle. Its therapeutics are designed to target the underlying mechanisms of aging, with applications in stroke recovery, Alzheimer's disease, coronary artery disease, and Type 2 diabetes. Through its innovative approach, Elevian seeks to prevent and treat the effects of aging by enhancing the body's natural repair and regeneration processes.

Wellth

Series A in 2020
Wellth is a digital health company based in New York that aims to enhance treatment adherence among individuals with chronic conditions. By leveraging behavioral economics, Wellth addresses the barriers that hinder patients from forming healthy habits and effectively managing their diseases. The company operates a mobile application that provides targeted incentive plans, reminders, and information to motivate users to engage in preventive health behaviors. Its platform not only empowers consumers to improve their adherence to medication and care plans but also helps reduce preventable hospitalizations and healthcare costs. Wellth's approach includes proven outcomes demonstrated through randomized controlled trials, making it a valuable solution for insurers and healthcare providers seeking to improve population health. Through its user-friendly application, Wellth supports members in establishing sustainable healthy habits while generating cost savings for payors.

Celevity

Seed Round in 2020
Celevity is a seed-stage company that develops drugs to help dogs live longer, healthier lives. It sees aging as a disease that is able to be slowed and improved with medicines. It was spun out of Laura Deming’s The Longevity Fund. Celevity is headquartered in San Francisco, California.

Epirium Bio

Series A in 2019
Epirium Bio, Inc. is a San Diego-based biopharmaceutical company focused on developing therapeutic compounds for cardiovascular diseases, metabolic syndrome, and various conditions related to mitochondrial dysfunction. Founded in 2008 and previously known as Cardero Therapeutics, Epirium Bio utilizes innovative insights into mitochondrial biology and tissue regeneration to create small molecule therapies. The company's research is aimed at enhancing muscle strength and supporting the treatment of neuromuscular and neurodegenerative disorders, including conditions such as muscular dystrophy. Through its novel approaches, Epirium Bio seeks to provide clinically significant solutions for patients suffering from these challenging diseases.

Exo

Series B in 2019
Exo is a medical device startup focused on developing a handheld ultrasound platform for imaging and therapeutic applications. The company aims to provide affordable and user-friendly medical imaging solutions for healthcare professionals globally. By integrating advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost efficiencies of semiconductor manufacturing, Exo significantly lowers the costs associated with medical imaging. This technology allows healthcare providers to make vital, real-time decisions that enhance patient outcomes. Exo's commitment to high-quality, accessible imaging represents a significant advancement in medical technology, making effective diagnostic tools available at an unprecedented price point.

Deciduous Therapeutics

Venture Round in 2019
Deciduous Therapeutics is a biotechnology company focused on developing innovative immune-modulatory therapies aimed at treating age-related diseases. The company specializes in novel therapeutics that activate the body's natural immune surveillance mechanisms to selectively eliminate senescent cells, which are associated with various age-related health issues. By promoting the clearance of these cells, Deciduous Therapeutics seeks to enhance healthspan and potentially improve the quality of life for individuals experiencing the effects of aging. The company is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, who has founded multiple biotech ventures.

Fauna Bio

Seed Round in 2019
Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, founded in 2018. It specializes in developing a cross-mammal drug discovery platform aimed at treating human diseases, including heart disease and neurodegenerative disorders. By studying the mechanisms that allow certain animals, such as hibernating and deep-diving species, to withstand extreme conditions, Fauna Bio seeks to uncover insights that can enhance human health. The company utilizes animal genomics, transcriptomics, metabolomics, and proteomics data from a diverse range of species to identify novel drug targets and facilitate pre-clinical and early clinical testing of new therapeutics. Through its innovative approach, Fauna Bio aims to improve recovery from serious medical events like trauma, heart attacks, and strokes.

Spring Discovery

Series A in 2018
Spring Discovery, Inc. is a biotechnology company based in Palo Alto, California, focused on advancing the discovery of therapies aimed at aging and related diseases. By utilizing a machine learning-based platform, the company targets the biological processes of aging to identify potential treatments for various age-related conditions, including cardiovascular and neurodegenerative diseases. The innovative approach of leveraging machine learning enhances the efficiency of experimentation, facilitating the rapid development of new therapies designed to increase healthy lifespans.

Gordian Biotechnology

Seed Round in 2018
Gordian Biotechnology, Inc. is a therapeutics company based in San Francisco, California, founded in 2018. The company specializes in developing a novel screening platform aimed at enhancing the efficiency of drug development for complex age-related diseases. Through its gene therapy discovery platform, Gordian focuses on researching and creating therapeutic drugs that address issues associated with premature aging, ultimately enabling medical professionals to treat age-related conditions and improve patient outcomes, including skin health.

System1 Biosciences

Series A in 2018
System1 Biosciences, Inc., is a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. System1 combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These “deep phenotypes” are exploited to identify novel therapeutic targets and drug treatments.

Decibel Therapeutics

Series C in 2018
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.

Precision BioSciences

Series B in 2018
Precision BioSciences, Inc. is a biotechnology company based in Durham, North Carolina, focused on genome editing and the development of therapeutic products. Utilizing its proprietary ARCUS genome editing platform, the company aims to create innovative solutions for human diseases and food applications. Precision BioSciences operates through two primary segments: Therapeutic and Food. The Therapeutic segment is engaged in developing allogeneic CAR T immunotherapies, with several candidates in clinical trials targeting various types of cancers, including acute lymphoblastic leukemia and multiple myeloma. Additionally, the company is involved in in vivo gene correction activities and has collaborations for developing treatments for chronic Hepatitis B. The Food segment concentrates on creating nutrition products. Founded in 2006, Precision BioSciences is dedicated to translating advanced gene editing technology into impactful products across the life sciences.

Unity Biotechnology

Series C in 2018
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

Spring Discovery

Seed Round in 2018
Spring Discovery, Inc. is a biotechnology company based in Palo Alto, California, focused on advancing the discovery of therapies aimed at aging and related diseases. By utilizing a machine learning-based platform, the company targets the biological processes of aging to identify potential treatments for various age-related conditions, including cardiovascular and neurodegenerative diseases. The innovative approach of leveraging machine learning enhances the efficiency of experimentation, facilitating the rapid development of new therapies designed to increase healthy lifespans.

Precision BioSciences

Series A in 2015
Precision BioSciences, Inc. is a biotechnology company based in Durham, North Carolina, focused on genome editing and the development of therapeutic products. Utilizing its proprietary ARCUS genome editing platform, the company aims to create innovative solutions for human diseases and food applications. Precision BioSciences operates through two primary segments: Therapeutic and Food. The Therapeutic segment is engaged in developing allogeneic CAR T immunotherapies, with several candidates in clinical trials targeting various types of cancers, including acute lymphoblastic leukemia and multiple myeloma. Additionally, the company is involved in in vivo gene correction activities and has collaborations for developing treatments for chronic Hepatitis B. The Food segment concentrates on creating nutrition products. Founded in 2006, Precision BioSciences is dedicated to translating advanced gene editing technology into impactful products across the life sciences.

ALX Oncology

Series A in 2015
ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies for cancer, particularly through its lead product candidate, ALX148, which targets the CD47 protein. This therapeutic aims to enhance the immune system's ability to detect and eliminate cancer cells, which often use CD47 as a mechanism to evade immune response. ALX148 is being investigated for its potential in treating various hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors such as head and neck squamous cell carcinoma and HER2-positive gastric cancer. The company’s research is rooted in advanced protein engineering, with a focus on creating next-generation therapies that minimize the hematologic toxicities associated with traditional CD47 blocking strategies.

Navitor Pharmaceuticals

Series A in 2014
Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.